

『BTCSCC 在嚴峻 COVID-19 疫情考驗下，謹守政府衛生福利部疾病管制署防疫規定，如常提供 CT 與 WORK UP、收集與提供造血幹細胞的作業。

During the period of the serious COVID-19 outbreak, BTCSCC maintains its stem cell donations as the usual process but follows the policies declared by the Ministry of Health and Welfare, Taiwan.

為預防非親屬間造血幹細胞捐贈者與受贈者免於感染到新型冠狀病毒肺炎的風險，在中央流行疫情指揮中心仍在運作時期(即風險尚未解除前)，本中心相關因應如下：

To prevent the risk of non-related donors and recipients from getting an infection by COVID-19 while the Central Epidemic Command Center is still serving (before the risk of the infection is dismissed), the measures taken by BTCSCC are as follows:

1. 為了解捐贈者感染新型冠狀病毒肺炎之風險，本中心將針對配對已確認、體檢及即將捐贈的捐者發出問卷，若捐者有相關症狀、接觸史或疫區旅遊史，將予該捐贈流程階段延後兩至三周以進行相關措施，若有確認無法捐贈或需延後之情形，本中心將盡速通知移植醫院。

To clarify the risk of infection on donors, BTCSCC will survey the donors at CT and Work Up stages. If the donors have related symptoms, history of contact with COVID-19 cases or have been exposed to the risk area, the donation process on the donors will be deferred for 2 to 3 weeks. The TC will be notified once an ineligibility or deferral is determined.

2. 捐者體檢與捐贈時，可經由健保卡再次評估捐者是否有疫區旅遊史。捐者

於體檢時發現相關病史、症狀或胸部影像學上異常，將予捐贈流程暫停並通知移植醫院。

At the donors' work up stage, travel history of the donors will be revealed by the national health insurance system. The work up will be postponed once a related medical history, symptoms or any adverse sign on the donors' chest imaging are observed. And the TC will be notified as soon as possible.

3. 捐贈前 14 天，請捐者再次填寫問卷，評估捐者是否有感染到新型冠狀病毒肺炎的風險。

BTCSCC will survey the donors 14 days before the collections to determine if they are at the risk of a COVID-19 infection.

4. BTCSCC 同仁每隔 2 週電話關懷捐贈者身體狀況，是否有異常徵候。

BTCSCC staff will call and perform a health survey on the donation candidate every two weeks to see if there is any abnormal symptom.

5. 完成捐贈幹細胞 14 天後，本中心將再次評估捐者是否有感染到新型冠狀病毒肺炎的風險，並通知移植醫院，以提供移植醫師做為各項臨床判斷處置之依據。

BTCSCC will also survey the donors 14 days after the collections to determine if the donors are at the risk of COVID-19 infection and notify the TC as the supportive information for clinical purposes.

6. 移植醫院往後請以 Dh 來取代 D0，讓 BTCSCC 知道取回造血幹細胞日期，

但 Dh 可能因航班變動或邊境封鎖，不保證造血幹細胞當天可以抵達。

病患的殲滅治療(conditioning therapy)或清髓療法(myeloablative conditioning therapy)要在造血幹細胞抵達後再開始。

造血幹細胞請先冷凍保存，此舉在各國疫情變動快速的階段，得以確保病患安全。

The TC should arrange a pick up date based on Dh (Day harvest) instead of Day0 with BTCSCC in the future. Dh may change and the product may not be able to arrive at the TC on the scheduled date due to flight changes or border closures.

Please start the conditioning therapy or myeloablative conditioning therapy of the recipient after the arrivals of the products. And the product should be cryopreserved prior to the completion of the therapy.

This strategy is to ensure the safety of the recipients in this rapidly changing epidemic situation.

7. 海外各骨髓庫或移植醫院請先確認飛機航班與雙邊國境防疫相關規定，再安排取回造血幹細胞，以維護造血幹細胞捐贈的順利與安全。

All the registries or the TCs should confirm the flight schedules and the regulations for epidemic prevention of both import and export

countries before arranging the pick-up date of the products to ensure the process of the donation is smooth and timely.

8 . 提供周邊血幹細胞及淋巴球之冷凍低溫運送服務，相關細節請洽中心同仁。

Using dry shipper, BTCSCC provides cryopreserved product of PBSCs and lymphocytes. For further information please contact coordinators of BTCSCC.

9 . 請各移植合作醫院務必回覆移植後追蹤表單，以供中心了解幹細胞使用狀況及病患輸注後情形。

TC must report the product receipt form to BTCSCC in order to understand the status of the product and its recipient.